← back to search

Ingrid E. Wertz

Gene Therapy Laboratory · FR
🔎 Find collaborators in Molecular Biology · Cancer Research →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Molecular Biology · Cancer Research
Research interest
Research focused on Ubiquitin and Deubiquitinating enzyme, with related work in Proteasome, Cell biology, Haploinsufficiency. Notable publications include 'Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease', 'Ubiquitination in the regulation of inflammatory cell death and cancer', and 'USP7 small-molecule inhibitors interfere with ubiquitin binding'.
h-index
citations
2,594
works
23
NIH funding
primary concept
email

Recent publications

The E3-ome gene-centric compendium reveals the human E3 ligase landscape
Cell 2026cited by 5position: middledoi
Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases
Cell chemical biology 2025cited by 1position: lastdoi
Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
eLife 2024cited by 2position: middledoi
Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
eLife 2024cited by 2position: middledoi
Targeting the Hippo pathway in cancers via ubiquitination dependent TEAD degradation
eLife 2024cited by 1position: middledoi
Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
American Journal of Hematology 2023cited by 26position: lastdoi
Targeted degradation via direct 26S proteasome recruitment
Nature Chemical Biology 2022cited by 108position: middledoi
Targeted protein degradation: from small molecules to complex organelles—a Keystone Symposia report
Annals of the New York Academy of Sciences 2022cited by 8position: middledoi
Ubiquitination in the regulation of inflammatory cell death and cancer
Cell Death and Differentiation 2021cited by 495position: middledoi
Identifying transcriptional programs underlying cancer drug response with TraCe-seq
Nature Biotechnology 2021cited by 55position: middledoi
Antibody toolkit reveals N-terminally ubiquitinated substrates of UBE2W
Nature Communications 2021cited by 22position: middledoi
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Cell 2019cited by 223position: middledoi
Denisovan, modern human and mouse TNFAIP3 alleles tune A20 phosphorylation and immunity
Nature Immunology 2019cited by 73position: middledoi
Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms
Drug Discovery Today Technologies 2019cited by 48position: firstdoi
From Discovery to Bedside: Targeting the Ubiquitin System
Cell chemical biology 2018cited by 153position: firstdoi
Reactive-site-centric chemoproteomics identifies a distinct class of deubiquitinase enzymes
Nature Communications 2018cited by 87position: lastdoi
USP7 small-molecule inhibitors interfere with ubiquitin binding
Nature 2017cited by 339position: lastdoi
Activity‐based probes for the ubiquitin conjugation–deconjugation machinery: new chemistries, new tools, and new insights
FEBS Journal 2017cited by 120position: lastdoi
Activity‐based probes for the multicatalytic proteasome
FEBS Journal 2017cited by 38position: middledoi
Molecular Understanding of USP7 Substrate Recognition and C-Terminal Activation
Structure 2016cited by 105position: middledoi
Length Matters: MINDY Is a New Deubiquitinase Family that Preferentially Cleaves Long Polyubiquitin Chains
Molecular Cell 2016cited by 15position: lastdoi
Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease
Nature Genetics 2015cited by 622position: middledoi
Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics
Trends in Pharmacological Sciences 2014cited by 46position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Till Maurer · Gene Therapy Laboratory3 papers (2016–2018)Matthew Bogyo · Palo Alto University3 papers (2017–2018)David S. Hewings · Gene Therapy Laboratory3 papers (2017–2018)John A. Flygare · Amgen (United States)3 papers (2017–2018) · 3 papers (2021–2025)Robert A. Blake · Gene Therapy Laboratory2 papers (2022–2025)Kebing Yu · Brown University2 papers (2018–2025) · 2 papers (2018–2021) · 2 papers (2022–2025)Scott A. Foster · Jazz Pharmaceuticals (France)2 papers (2021–2022) · 2 papers (2021–2022)Jeremy Murray · Gene Therapy Laboratory2 papers (2016–2019)William F. Forrest · Gene Therapy Laboratory2 papers (2018–2025)Wayne J. Fairbrother · Amgen (United States)2 papers (2022–2025)Nataliya Popovych · University of Michigan–Ann Arbor2 papers (2018–2022)Jennie R. Lill · Gene Therapy Laboratory2 papers (2014–2021)Suzie J. Scales · Amgen (United States)1 papers (2022–2022) · 1 papers (2021–2021) · 1 papers (2018–2018) · 1 papers (2022–2022)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Molecular Biology · Cancer Research →